サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1635981

高リン血症治療薬市場レポート：製品別、剤形別、流通チャネル別、地域別、2025-2033年

Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 137 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
高リン血症治療薬市場レポート：製品別、剤形別、流通チャネル別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

高リン血症治療薬の市場の世界市場規模は2024年に44億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに82億米ドルに達し、2025年から2033年にかけて6.72%の成長率（CAGR）を示すと予測しています。末期腎臓病（ESKD）の有病率の上昇、慢性疾患を開発しやすい高齢者人口の大幅な増加、および疾患の早期診断の傾向の高まりに起因する健康意識の高まりは、市場を牽引する主な要因のいくつかを表しています。

高リン血症は、リン酸塩の摂取量の増加、細胞外へのリン酸塩の移動、リン酸塩の排泄量の減少の結果、血液中のリン酸塩レベルが上昇することを特徴とします。高リン血症は、慢性腎臓病、糖尿病性ケトアシドーシス、コントロールされていない糖尿病、および副甲状腺ホルモンレベルの低下を患っている人に頻繁に認められます。高リン血症の治療薬は、リン酸塩結合剤を含む傾向があり、血中のリン酸塩濃度が高くなるのを抑制するのに役立ちます。さらに、高リン血症治療薬は、消化管からのリン吸収を抑制する効果があります。高リン血症治療薬は、陰イオンのリン酸塩を炭酸塩、酢酸塩、オキシ水酸化物、クエン酸塩などの活性陽イオンと交換し、吸収されずに排泄される化合物を形成します。

高リン血症治療薬の市場傾向：

世界中で様々な慢性疾患、特に末期腎臓病（ESKD）の有病率が上昇していることは、市場の成長を促す重要な要因です。これは、これらの疾患を開発しやすい高齢者人口の大幅な増加に起因しています。これに伴い、新薬の承認による製品上市の増加が市場にプラスの影響を与えています。また、多くの臨床試験で有力なパイプライン医薬品がイントロダクションされ、市場に有利な成長機会が生まれています。しかし、高リン血症治療薬の副作用の増加、数カ国の医薬品管理機関による規制の厳格化、高い製造コストが市場の成長を抑制しています。逆に、医薬品製造手順における広範な研究開発（R&D）活動は、市場に明るい見通しをもたらしています。これとは別に、地域的プレゼンスを拡大するための主要企業による共同研究、提携、戦略的合併・買収（M&A）の大幅な増加も市場に弾みをつけています。さらに、従来のリン酸塩結合剤から非リン酸塩結合剤の採用へと嗜好が変化していることも、市場を後押ししています。さらに、医療費の増加やヘルスケア・インフラ施設の継続的な技術向上も市場を後押ししています。その他、急速な都市化、製品のプレミアム化、疾病の早期診断傾向の高まり、バイオテクノロジー産業の大幅な成長、可処分所得水準の上昇なども市場に寄与しています。

本レポートで扱う主な質問

  • 世界の高リン血症治療薬の市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 世界の高リン血症治療薬の市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的な高リン血症治療薬市場はどの国か？
  • 製品別の市場内訳は？
  • 剤形別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 世界の高リン血症治療薬の市場の競合構造は？
  • 世界の高リン血症治療薬の市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の高リン血症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • セベラマー
    • 市場動向
    • 市場予測
  • カルシウム系リン酸結合剤
    • 市場動向
    • 市場予測
  • 鉄系リン酸結合剤
    • 市場動向
    • 市場予測
  • 炭酸ランタン
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：剤形別

  • 錠剤
    • 市場動向
    • 市場予測
  • シロップ
    • 市場動向
    • 市場予測
  • カプセル
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Ardelyx Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Lupin Pharmaceuticals Inc（Lupin Limited）
    • Torii Pharmaceutical Co. Ltd.（Japan Tobacco Inc.）
    • Vifor Pharma Management Ltd.（CSL Limited）
図表

List of Figures

  • Figure 1: Global: Hyperphosphatemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperphosphatemia Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hyperphosphatemia Drugs Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Hyperphosphatemia Drugs Market: Breakup by Dosage Form (in %), 2024
  • Figure 6: Global: Hyperphosphatemia Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Hyperphosphatemia Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Hyperphosphatemia Drugs (Sevelamer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Hyperphosphatemia Drugs (Sevelamer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Hyperphosphatemia Drugs (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Hyperphosphatemia Drugs (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Hyperphosphatemia Drugs (Tablets) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Hyperphosphatemia Drugs (Tablets) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Hyperphosphatemia Drugs (Syrups) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Hyperphosphatemia Drugs (Syrups) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Hyperphosphatemia Drugs (Capsules) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Hyperphosphatemia Drugs (Capsules) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Hyperphosphatemia Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Hyperphosphatemia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Hyperphosphatemia Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Hyperphosphatemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperphosphatemia Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
  • Table 4: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Hyperphosphatemia Drugs Market: Competitive Structure
  • Table 7: Global: Hyperphosphatemia Drugs Market: Key Players
目次
Product Code: SR112025A6746

The global hyperphosphatemia drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.72% during 2025-2033. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:

The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.

Key Market Segmentation:

Product Insights:

  • Sevelamer
  • Calcium Based Phosphate Binders
  • Iron Based Phosphate Binders
  • Lanthanum Carbonate
  • Others

Dosage Form Insights:

  • Tablets
  • Syrups
  • Capsules

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive hyperphosphatemia drugs markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the dosage form?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global hyperphosphatemia drugs market?
  • Who are the key players/companies in the global hyperphosphatemia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperphosphatemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Sevelamer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcium Based Phosphate Binders
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Iron Based Phosphate Binders
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Lanthanum Carbonate
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Dosage Form

  • 7.1 Tablets
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Syrups
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Capsules
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ardelyx Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Fresenius Medical Care AG & Co. KGaA
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.